newsCHMP’s September 2023 meeting highlights18 September 2023 | By Catherine Eckford (European Pharmaceutical Review)In its September 2023 meeting, the EMA’s human medicines committee (CHMP) recommended nine medicines for approval and the extension of therapeutic indications for 11 medicines.
newsGilead opens paediatric drug development centre in Ireland7 April 2022 | By Hannah Balfour (European Pharmaceutical Review)The new global paediatric drug development centre of excellence will focus on the creation of paediatric formulations to treat some of the world's most challenging viral diseases.
news3D-printed vaccine patch boasts greater immunity than usual vaccine shot27 September 2021 | By Anna Begley (European Pharmaceutical Review)A newly designed 3D-printed microneedle patch demonstrated immune responses 50 times greater than typical subcutaneous injection in animals.
newsGlobal pharma contract manufacturing market to value $120bn by 20275 August 2021 | By Hannah Balfour (European Pharmaceutical Review)Growth in the pharmaceutical contract manufacturing market to be driven by advanced technologies, the rising aging population and the increase in chronic disease cases, says report.
newsTherapeutic proteins and oral vaccines market to surpass $300,000mn by 202715 February 2021 | By Hannah Balfour (European Pharmaceutical Review)The market is expected to grow at a 6.7 percent CAGR, driven by the increasing prevalence of cancer and cardiovascular diseases, as well as growing interest in biologics.
newsLeaked document reveals ‘unprecedented’ medicine shortages in NHS19 November 2019 | By Jim Swarbrick (European Pharmaceutical Review)A document from the DHSC has reportedly advised NHS doctors to ration certain medicines after outlining dozens of drugs that are in shortage, as published in a report.
newsGilead’s Phase II study showed 99% HCV cure rates26 April 2017 | By Niamh Marriott, Junior EditorGilead Sciences’ Phase II studies demonstrated HCV cure rates of 99% in children, and 100% in patients co-infected with HCV and hepatitis B virus...
newsFDA approves Roche’s blood screening assay for donor screening24 October 2016 | By Niamh Louise Marriott, Digital Content ProducerThe cobas MPX assay enables donor screening laboratories to apply the most advanced PCR-based diagnostic technology to the surveillance of donated blood...
newsAbbVie receives FDA approval for new Hepatitis C drug27 July 2016 | By Niamh Louise Marriott, Digital Content ProducerUS FDA has approved Viekira XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the treatment of chronic genotype 1 (GT1) hepatitis C...
newsFDA approves Epclusa for treatment of chronic HCV29 June 2016 | By Victoria White, Digital Content ProducerEpclusa is the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection...
newsPositive CHMP opinion for Gilead’s Epclusa in HCV27 May 2016 | By Victoria White, Digital Content ProducerThe EMA’s CHMP has adopted a positive opinion on Gilead’s Epclusa for the treatment of chronic hepatitis C virus...
newsAbbVie presents data for ABT-493 and ABT-530 regimen in HCV18 April 2016 | By Victoria White, Digital Content ProducerWith eight weeks of treatment, 97-98 percent of GT1-3 HCV infected patients without cirrhosis treated with ABT-493 and ABT-530 achieved sustained SVR12...
newsGilead announces results from two Phase III studies of TAF in HBV15 April 2016 | By Victoria White, Digital Content ProducerStudies 108 and 110 were 48-week clinical trials evaluating TAF among 1,298 treatment-naïve and treatment-experienced patients with chronic HBV infection...
newsAbbVie presents real-world data for Viekirax + Exviera in HCV15 April 2016 | By Victoria White, Digital Content ProducerAbbVie has announced new real-world data for Viekirax and Exviera, showing 96% of GT1 HCV patients and 100% of GT4 patients achieved SVR12...
newsPositive results for AbbVie’s Viekirax + Exviera regimen14 April 2016 | By Victoria White, Digital Content ProducerAbbVie announced high SVR sates with Viekirax + Exviera regardless of the presence of resistance-associated variants prior to treatment in GT1 chronic HCV patients...
![Gilead sign at their headquarters in Silicon Valley, California USA[Credit: Michael Vi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Gilead-2-300x278.jpg)
![Gilead sign at their headquarters in Silicon Valley, California USA[Credit: Michael Vi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Gilead-2-e1642427117214.jpg)
![Male Thai child receiving oral polio vaccine from healthcare worker [Credit: frank60 / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Oral-vaccine-300x278.jpg)
![Male Thai child receiving oral polio vaccine from healthcare worker [Credit: frank60 / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Oral-vaccine.jpg)
